Monte Rosa Therapeutics, Inc. (GLUE) P/E Ratio History
Deep ValueTrading at -37.2x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2025–2025
Loading P/E history...
P/E Ratio Analysis
As of June 12, 2026, Monte Rosa Therapeutics, Inc. (GLUE) trades at a price-to-earnings ratio of -37.2x, with a stock price of $17.10 and trailing twelve-month earnings per share of $-1.98.
The current P/E is 208% below its 5-year average of 34.4x. Over the past five years, GLUE's P/E has ranged from a low of 12.9x to a high of 66.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.1x, GLUE trades at a 261% discount to its sector peers. The sector includes 235 companies with P/E ratios ranging from 0.0x to 187.5x.
Relative to the broader market, GLUE trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GLUE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GLUE Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
GLUE P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $113B | 29.0Lowest | 3.51 | +837%Best | |
| $14B | 31.1 | 0.98Best | +21% | |
| $8B | 155.0 | - | +287% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
GLUE Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | - | $7.41 | $0.31 | 23.9x | -30% |
| FY2025 Q2 | Jun 30 2025 | $4.51 | $0.35 | 12.9x | -62% |
| FY2025 Q1 | Mar 31 2025 | $4.64 | $0.07 | 66.3x | +93% |
Average P/E for displayed period: 34.4x
What if you invested $1,000 in GLUE back in 2025?
Total return with dividends reinvested · 1+ years of data
Calculate ReturnsHow much would $100/month in GLUE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs GLUE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationGLUE vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowGLUE — Frequently Asked Questions
Quick answers to the most common questions about buying GLUE stock.
What is GLUE's P/E ratio?
Monte Rosa Therapeutics, Inc. (GLUE) trailing twelve-month P/E ratio is -37.2x, based on TTM diluted EPS of $-1.98. The 5-year average P/E is 34.4x and the historical range spans 12.9x to 66.3x.
Is GLUE stock overvalued or undervalued?
GLUE trades at -37.2x P/E, below its 5-year average of 34.4x. At the 0th percentile of its historical range (12.9x–66.3x), the stock is priced at a discount to its own history.
Is GLUE stock expensive?
No, GLUE is not expensive on a historical basis. The current P/E of -37.2x is below the 5-year average of 34.4x and sits at the 0th percentile of its valuation range.
What is GLUE's historical P/E range?
Over the past 5 years, GLUE's P/E ratio has ranged from 12.9x to 66.3x, with a median of 23.9x and an average of 34.4x. The current P/E of -37.2x places the stock at the 0th percentile of this range. Full historical data spans 2025–2025.
How does GLUE's P/E compare to the S&P 500?
GLUE trades at -37.2x P/E versus the S&P 500 median of 24.9x. The 249% discount to the market suggests lower growth expectations or perceived higher risk.
How does GLUE's valuation compare to Healthcare peers?
Monte Rosa Therapeutics, Inc. P/E of -37.2x compares to the Healthcare sector median of 23.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is GLUE's PEG ratio?
GLUE PEG ratio is N/A, based on a P/E of -37.2x and EPS growth of 53.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is GLUE's earnings yield?
GLUE earnings yield is N/A, the inverse of its -37.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.